Market Overview:

The 7 major obesity markets reached a value of USD 25.8 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 150.5 Billion by 2035, exhibiting a growth rate (CAGR) of 17.31% during 2025-2035.

Report Attribute
Key Statistics
Base Year  2024
Forecast Years  2025-2035
Historical Years 
2019-2024
Market Size in 2024
 USD 25.8 Billion
Market Forecast in 2035
 USD 150.5 Billion
Market Growth Rate 2025-2035
 17.31%


The obesity market has been comprehensively analyzed in IMARC's new report titled "Obesity Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035". Obesity is a complex, chronic disease characterized by an excessive amount of body fat. The World Health Organization (WHO) defines overweight and obesity as abnormal or excessive fat accumulation that may impair health. It is commonly diagnosed using the Body Mass Index (BMI), with a BMI of 30 or above indicating obesity. The condition increases the risk of numerous health problems, including type 2 diabetes, cardiovascular diseases, hypertension, certain types of cancer, and musculoskeletal disorders. Diagnosis typically involves a physical examination, measurement of height and weight to calculate BMI, and waist circumference measurement. Blood tests to check cholesterol, blood sugar, and liver function may also be conducted to assess for related comorbidities.

Obesity Market

The primary driver for the obesity market is the soaring global prevalence of the condition, fueled by sedentary lifestyles, and the widespread availability of high-calorie, processed foods. This has created a substantial and growing patient population in need of effective treatments. A major catalyst for market growth has been the introduction and widespread adoption of highly effective new drug classes, particularly GLP-1 receptor agonists like semaglutide and tirzepatide. These therapies have demonstrated unprecedented weight loss efficacy, transforming the treatment landscape and driving significant market expansion. Additionally, there is a growing recognition of obesity as a chronic disease by healthcare providers and payers, which is leading to improved reimbursement and coverage for anti-obesity medications. This shift is removing significant barriers to access and encouraging more patients to seek medical treatment. The robust pipeline of next-generation therapies, including oral formulations, multi-receptor agonists, and novel mechanisms of action, promises to offer even more effective and convenient treatment options, which is expected to further propel the obesity market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the obesity market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for obesity and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the obesity market in any manner.

Recent Developments:

In February 2025, Eli Lilly and Company announced positive top-line results from its SURPASS-4 clinical trial, which evaluated retatrutide in adults with obesity and cardiovascular comorbidities. The trial met its primary endpoint, demonstrating superior weight loss compared to placebo, and showed significant improvements in key secondary endpoints, including blood pressure and lipid levels.

In December 2024, Novo Nordisk announced a major investment to expand its manufacturing facilities in Denmark and the United States to increase the supply of its popular GLP-1 products, Wegovy (semaglutide) and Ozempic. This expansion aims to address the high global demand and persistent supply shortages for these medications.

In November 2024, Amgen presented new long-term data for its investigational drug MariTide (maridebart cafraglutide) at a major medical conference. The data from the Phase 2 extension study showed sustained and even continued weight loss for patients remaining on the therapy beyond one year, reinforcing its potential as a long-acting treatment option.

Drugs:

Wegovy (Semaglutide) is an injectable glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. It works by mimicking the effects of the natural GLP-1 hormone, which targets areas of the brain that regulate appetite and food intake. This leads to reduced hunger, increased feelings of fullness, and consequently, lower calorie consumption and significant weight loss. It is administered once weekly via subcutaneous injection.

Zepbound (Tirzepatide), developed by Eli Lilly and Company, is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. By activating both receptors, tirzepatide provides a synergistic effect on appetite regulation and glucose metabolism, leading to even greater weight loss than GLP-1 agonists alone. It is also a once-weekly injectable medication approved for chronic weight management.

Retatrutide (LY3437943) is an investigational triple-hormone-receptor agonist being developed by Eli Lilly and Company. It targets the GLP-1, GIP, and glucagon receptors. The activation of the glucagon receptor is believed to increase energy expenditure, which, combined with the appetite-suppressing effects of GLP-1 and GIP agonism, has the potential to produce a higher degree of weight loss than existing therapies.

MariTide (Maridebart cafraglutide, AMG 133), developed by Amgen, is an investigational bispecific molecule that combines a GLP-1 receptor agonist with a GIP receptor antagonist. This novel mechanism aims to promote weight loss through GLP-1 agonism while blocking the GIP receptor, which may have a role in fat storage. A key potential advantage is its less frequent dosing schedule, possibly monthly or even less often.

Time Period of the Study

Countries Covered

Analysis Covered Across Each Country

Competitive Landscape:

This report also provides a detailed analysis of the current obesity marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Late-Stage Pipeline Drugs

Drugs Company Name
Wegovy (Semaglutide) Novo Nordisk
Zepbound (Tirzepatide) Eli Lilly and Company
Saxenda (Liraglutide) Novo Nordisk
Contrave (Bupropion/naltrexone) Currax Pharmaceuticals LLC
Qsymia (Phentermine/topiramate) VIVUS LLC
MariTide (Maridebart cafraglutide) Amgen
Retatrutide (LY3437943) Eli Lilly and Company
Survodutide (BI 456906) Boehringer Ingelheim / Zealand Pharma
Orforglipron (LY3502970) Eli Lilly and Company
CT-996 Carmot Therapeutics (A Roche Company)


*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

Epidemiology Insights

Obesity: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

Need more help?